Novotech invests in trial management with Oracle

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/undefined undefined)
(Image: Getty/undefined undefined)

Related tags: trial transparency, Management, Asia, Asia pacific, CRO, Investment

Novotech will add Oracle’s trial management service, to support its footprint within the Asia-Pacific region.

Novotech, a contract research organization (CRO) based in the Asia-Pacific, will implement Oracle’s Trial Management and Monitoring Cloud Service (TMMCS). The company said this will enable it to have the largest trial management system in the region.

This investment, which establishes Novotech as the first to implement the TMMCS in the Asia-Pacific, is the latest in a series of ongoing investments for the CRO.

The company stated its recent investments ensure regulatory compliance and integration into global studies, allowing Novotech to have the capability to present better data visibility to, in turn, improve decision-making.

In a statement, John Moller, CEO of Novotech, stated that the technology “provides a centralized trial database enabling improved access, control and governance of clinical data.”

He further stated that the system allows for functionalities like eSignatures and tools that may enable faster approvals and submissions, therefore accelerating trial implementation.

Novotech expansion

In the Asia-Pacific region, Novotech says its clinical staff employment has risen 20% over the last quarter. This growth is thought to be fueled by demand for a CRO within the region.

In addition, the CRO has recently signed 10 strategic collaborations with hospitals and research institutions within the region.

 

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars